Valuation: ImmuCell Corporation

Market Cap 96.45M 86.54M 80.01M 72.46M 135M 9.19B 137M 957M 381M 4.81B 362M 354M 15.26B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 106M 94.96M 87.79M 79.51M 149M 10.08B 150M 1.05B 418M 5.27B 397M 389M 16.75B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.73%
Yield 2024 *
-
Yield 2025 -
1 day+3.51%
1 week+0.95%
Current month+8.37%
1 month+7.49%
3 months-5.52%
6 months+27.19%
Current year+72.68%
1 week 10.19
Extreme 10.19
10.64
1 month 9.55
Extreme 9.551
10.88
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 A Free

Chairman

11,933 0.1319%
4/15/26 A Free

Director

17,899 0.1979%
4/15/26 A Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
+3.51%+0.95%+72.40%+123.11% 96.45M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.55%+2.37%+54.15%+66.35% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+3.10%+3.48%+35.39%+57.58% 294B
+1.69%+0.05%+3.39%+27.09% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +2.13%+1.34%+44.48%+81.37% 403.73B
Weighted average by Cap. +2.30%+1.50%+45.03%+89.28%

Financials

2024 2025
Net sales 26.49M 23.77M 21.98M 19.9M 37.18M 2.52B 37.63M 263M 105M 1.32B 99.42M 97.32M 4.19B 27.64M 24.8M 22.93M 20.77M 38.8M 2.63B 39.27M 274M 109M 1.38B 104M 102M 4.37B
Net income -2.16M -1.93M -1.79M -1.62M -3.03M -205M -3.06M -21.39M -8.52M -107M -8.09M -7.92M -341M -1.04M -933K -863K -781K -1.46M -99.05M -1.48M -10.31M -4.11M -51.83M -3.9M -3.82M -165M
Net Debt 11.34M 10.18M 9.41M 8.52M 15.92M 1.08B 16.11M 112M 44.8M 565M 42.56M 41.66M 1.79B 9.39M 8.42M 7.79M 7.05M 13.18M 894M 13.34M 93.1M 37.08M 468M 35.23M 34.48M 1.49B
Projected Income Statement - Annual - ImmuCell Corporation
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
28/10/26 $10.62 +3.51% 924
27/10/26 $10.26 +0.20% 4,167
26/10/26 $10.24 -0.10% 2,557
23/10/26 $10.25 -1.82% 11,335
22/10/26 $10.44 -0.76% 5,772
  1. Stock Market
  2. Stocks
  3. ICCC Stock